Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Observational Study of Iris Tumors

NCT ID: NCT03809585Sponsor: Oregon Health and Science UniversityLast updated: 2025-09-09

Summary

This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.

Arms & interventions

Outcome measures

Primary

  • Tumor Thickness in Benign vs Malignant Iris Lesions

    OCT/OCTA will be used to compare tumor thickness measurements against the conventional Ultrasonic Biomicroscopy (UBM) device. Tumor thickness will be measured in millimeters, and growth of 0.5 mm or greater will be used to differentiate malignant from benign lesions.

    Time frame: 6 months

Secondary

  • Tumor Area in Benign vs Malignant Iris Lesions

    Time frame: 6 months

  • Tumor Volume in Benign vs Malignant Iris Lesions

    Time frame: 6 months

  • Effect of Radiation Treatment on Tumor and Surrounding Ocular Structures

    Time frame: 6 months after treatment

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: Yes
Inclusion Criteria for tumor group: * Eyes with diagnosis of melanotic or amelanotic iris tumors Inclusion Criteria for healthy control group: * Eyes without iris defects or lesions Exclusion Criteria (both groups): * Inability to give informed consent * Inability to maintain stable fixation for OCT imaging * Inability to commit to required study visits * Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation * Mature cataracts if found to limit visual potential to worse than 20/40

Study locations (1)

Oregon Health & Science University

Portland, Oregon, 97239

Recruiting
Denzil Romfh, OD · Contact
503-494-4351romfhd@ohsu.edu
Humberto Martinez, COT · Contact
503-494-7712martinhu@ohsu.edu
Observational Study of Iris Tumors | Cancerify